Table 6.
Base-case results for niraparib, RS, olaparib and rucaparib non-gBRCAmut
| Total costs (US$) | Total LYG | Total QALYs | Incremental costs (US$) | Incremental LYG | Incremental QALYs | ICER (US$) versus baseline (QALYs) | ICER (US$) incremental (QALYs) | |
|---|---|---|---|---|---|---|---|---|
| RS | 100,724 | 2.816 | 2.231 | – | – | – | – | – |
| Niraparib | 333,322 | 5.351 | 4.379 | 232,598 | 2.535 | 2.148 | 108,287 | 108,287 |
| Olaparib | 355,558 | 3.727 | 2.756 | 22,236 | − 1.623 | − 1.623 | 485,304 | Dominated |
| Rucaparib | 406,883 | 4.868 | 3.948 | 73,561 | − 0.483 | − 0.432 | 178,382 | Dominated |
ICER incremental cost-effectiveness ratio, LYG life-years gained, QALYs quality-adjusted life-years, RS routine surveillance